News

Valbenazine shows significant improvements in physical, social, and emotional outcomes for tardive dyskinesia patients, as revealed in a recent study.

Here's some of what is coming soon to NeurologyLive® this week.

The chief medical officer of Gain Therapeutics discusses GT-02287, a promising treatment for Parkinson that has shown strong safety and tolerability in an ongoing phase 1 trial. [WATCH TIME: 3 minutes]

New real-world data confirms the safety and tolerability of high-dose apomorphine infusion for advanced Parkinson's disease, enhancing treatment options.

A phase 2 study shows risvodetinib improves safety and symptoms in early Parkinson disease, suggesting potential as a disease-modifying therapy.

In this final episode, Riley Bove, MD, considers the next phase of MS research, emphasizing the need for innovative trial designs to address sequencing, discontinuation, and subgroup-specific treatment strategies.

New research highlights ecopipam's effectiveness in reducing Tourette syndrome symptoms and relapse risk in children, offering a promising treatment alternative.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on tardive dyskinesia.

In this clip, a multiple sclerosis expert reflects on how ofatumumab’s role has expanded since FDA approval in 2020, from first-line use to special populations, and what this means for daily practice.

Neurology News Network. for the week ending October 4, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 3, 2025.

Riley Bove, MD, an associate professor of neurology at UCSF, breaks down the ARTIOS phase 3b trial results, highlighting the exceptionally low relapse rates, MRI outcomes, and safety findings in patients switching therapies.

Bristol Myers Squibb's BMS-986446 receives FDA fast track designation, targeting tau protein to combat early-stage Alzheimer's disease in ongoing trials.

At ECTRIMS 2025, a staff neurologist at Cleveland Clinic discussed findings from an observational study on long-term safety risks of ocrelizumab in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 19 minutes]

Portable optical blood flow monitors can enhance prehospital stroke diagnosis, enabling faster, accurate triage for large vessel occlusions and improving patient outcomes.

In episode 1, Bove explores how ofatumumab, a B-cell–depleting therapy, stands apart from fingolimod and fumarates, and why its mechanism may offer distinct treatment advantages.

At AHS 2025, Eric Baron, DO, headache specialist at Cleveland Clinic, presented findings from a cross-sectional survey that examined psychedelic use among Canadian patients with migraine and cluster headache.

At ECTRIMS 2025, the postdoctoral research fellow at the University of Siena in Italy talked about how machine learning could classify multiple sclerosis into biologically distinct subtypes. [WATCH TIME: 5 minutes]

Nipocalimab receives positive EMA recommendation, potentially transforming treatment for generalized myasthenia gravis with significant clinical trial results.

Eli Lilly's donanemab gains EU approval, offering hope for early Alzheimer's treatment with a new dosing regimen that reduces side effects.

Xu Li, PhD, a research associate in the F.M. Kirby Research Center for Functional Brain Imaging at Kennedy Krieger Institute, provided commentary on a promising, recently published study using QSM MRI to detect cognitive changes in Alzheimer disease.

The president of the LGMD Foundation discussed raising awareness, strengthening advocacy, and the lived experience of navigating limb-girdle muscular dystrophy.

In a phase 3 trial presented at ECTRIMS 2025, ocrelizumab demonstrated noninferior relapse control compared with fingolimod in pediatric patients with relapsing-remitting multiple sclerosis.

The founder of the LGMD Foundation provided context on the significance behind LGMD Awareness Day, an initiative dedicated toward uplifting the limb-girdle muscular dystrophy community. [WATCH TIME: 6 minutes]

Primary results presented at ECTRIMS 2025 suggest that body-weight–adjusted high-dose of ocrelizumab did not further slow disease progression in patients with primary progressive multiple sclerosis.

Melissa Spencer, PhD, discussed the rare and complex landscape of limb girdle muscular dystrophy, highlighting research challenges, safety considerations in gene therapy, and the need for natural history studies and biomarkers.

Kelly Brazzo, founder and chief executive officer of the CureLGMD2i Foundation, provided commentary on LGMD Awareness Day, focusing on subtype-specific advocacy, genetic testing, and platform development leading to approved therapies.